Amadeus Invests in Inotec’s Advanced Woundcare Technology

Amadeus Capital Partners, a global technology investor, has invested in Inotec AMD, a maker of mobile medical devices designed to heal chronic hypoxic wounds. As more than 90 percent of wounds suffer from a lack of oxygen, the launch of Natrox addresses this concern with an application that treats a broad spectrum of chronic health problems.
 
Amadeus Capital Partners will bring investment and expertise to Inotec, based in Cambridge, United Kingdom, to enable the company to carry out large scale clinical trials outside the coountry and to broaden the scope of application of its Natrox family of products. The global will also draw on its worldwide network to help Inotec establish commercial agreements and grow its presence internationally.
 
“Inotec’s proprietary technology has the potential to profoundly improve standards of care for hard-to-heal and chronic wounds, a large and growing market, which has not been disrupted since negative therapy (VAC) was launched in the ‘90s. Being small and portable, Natrox can be used at home as well as in hospital, alleviating pressure on stretched healthcare systems and materially improving quality of life for patients,” said Pierre Socha, investment manager, Amadeus Capital Partners.
 
Inotec was established in 2005 by Professor Derek Fray from Cambridge University and Mel Vinton. The compact and wearable Natrox system, which is CE marked and approved by the U.S. Food and Drug Administration, provides a continuous supply of pure humidified oxygen to wounds. In preliminary trials, Natrox has been shown to reduce the size of chronic wounds substantially within weeks, with a large number of patients’ wounds reaching complete healing.
 
“The global wound-care market is projected to grow to $18.3 billion globally in 2019, driven in part by changing life styles and ageing populations in many countries. There are some 400 million diabetes sufferers around the world, some 60 million of whom are likely to develop a lower limb ulcer. Amadeus’ investment will enable us to deliver advanced and highly effective oxygen-based wound-care technology across the world,” noted Trevor Stanley, Inotec CEO.
 
Since its inception in 1997, Amadeus Capital Partners has raised more than $1 billion for investment and backed more than 100 companies in the software, mobile, internet, cyber security and medical technology sectors. The investment team— based in India, South Africa, Sweden, the United Kingdom and United States—has deep experience in technology and invests in high-growth companies from early stage to pre-IPO. 
 
Major businesses built by Amadeus include CSR, a connectivity, audio, imaging and location semiconductor company, now owned by Qualcomm; Solexa, the developer of next generation genetic analysis systems, merged into Illumina; Optos, the retinal imaging company, acquired by Nikon; ForeScout, a global enterprise security vendor; Octo Telematics, the provider of insurance telematics services acquired by Renova Group; and Tobii, the global innovator in eye tracking. 
 
Inotec AMD is a specialist wound care company based in Cambridge England. Formed specifically to introduce new technologies to healthcare professionals around the world and promote faster and better healing to patients, the company is positioning Natrox to be an integral part of global wound care treatment regimes in the coming years.